Medtronic plc(MDT) Stock Research - Grey Stern Research

Medtronic plc (MDT) Stock Analysis

$87.84 (-0.61%)

MDT Financial Performance


Use the table below to view Medtronic plc's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2025

Metric Value Ranking among Peers
Price $87.84 -
52 Week Low $75.96 -
52 Week High $92.68 -
Market Cap $112.6 Billion 4/10
Gross Margin 65% 6/10
Profit Margin 15% 3/10
EBITDA margin 0% 9/10
Q2 - 2025 Revenue $8.4 Billion 2/10
Q2 - 2025 Earnings $1.3 Billion 3/10
Q2 - 2025 Free Cash Flow $554.0 Billion 2/10
Trailing 4 Quarters Revenue $33.0 Billion 2/10
Trailing 4 Quarters Earnings $4.3 Billion 2/10
Quarterly Earnings Growth 40% 4/10
Annual Earnings Growth 31% 5/10
Quarterly Revenue Growth 5% 4/10
Annual Revenue Growth 6% 6/10
Cash On Hand $1.4 Billion 4/10
Short Term Debt $3.7 Billion 2/10
Long Term Debt $24.6 Billion 1/10

Medtronic plc Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Medtronic plc's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 26.26 8/10
PS 3.41 9/10
PB 2.31 8/10
PC 80.80 1/10
Liabilities to Equity 0.85 4/10
ROA 0.05 6/10
ROE 0.09 5/10
Current Ratio 2.18 6/10
Quick Ratio 0.03 9/10
Long Term Debt to Equity 0.51 4/10
Debt to Equity 0.58 4/10
Burn Rate 2.16 2/10
Cash to Cap 0.01 9/10
CCR 0.44 6/10
EV to EBITDA -4104.95 10/10
EV to Revenue 4.23 8/10

Company Details

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.

CEO: Mr. Omar Ishrak

Website: https://www.medtronic.com

Address: 20 On Hatch, Hatch Street Lower DUBLIN, DUBLIN

Exchange: New York Stock Exchange

Industry: Medical Devices

Medtronic plc Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Medtronic plc. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Boston Scientific Corporation BSX $147.8 Billion
Abbott Laboratories ABT $204.3 Billion
Zimmer Biomet Holdings, Inc. ZBH $21.8 Billion
Tandem Diabetes Care, Inc. TNDM $2.3 Billion
DexCom, Inc. DXCM $34.0 Billion
Edwards Lifesciences Corporation EW $40.7 Billion
Stryker Corporation SYK $148.9 Billion
Insulet Corporation PODD $19.6 Billion
Align Technology, Inc. ALGN $17.3 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
MDT Income Statements
Quarter Year Revenue Earnings
Q2 2025 $ 8.4 Billion $1.3 Billion
Q1 2025 $ 7.9 Billion $1.0 Billion
Q4 2024 $ 8.6 Billion $654.0 Million
Q3 2024 $ 8.1 Billion $1.3 Billion
Q2 2024 $ 8.0 Billion $909.0 Million
Q1 2024 $ 7.7 Billion $791.0 Million
Q4 2023 $ 8.5 Billion $1.2 Billion
Q3 2023 $ 7.7 Billion $1.2 Billion

View All

MDT Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2025 $1.4 Billion $90.0 Billion $28.3 Billion $48.7 Billion
Q1 2025 $1.3 Billion $89.7 Billion $27.9 Billion $48.2 Billion
Q4 2024 $1.3 Billion $90.0 Billion $25.0 Billion $50.4 Billion
Q3 2024 $1.6 Billion $90.8 Billion $25.2 Billion $52.0 Billion
Q2 2024 $1.3 Billion $90.1 Billion $25.1 Billion $51.6 Billion
Q1 2024 $1.3 Billion $90.8 Billion $25.0 Billion $51.2 Billion
Q4 2023 $1.5 Billion $90.9 Billion $24.4 Billion $51.5 Billion
Q3 2023 $4.5 Billion $94.1 Billion $28.1 Billion $51.4 Billion

View All

MDT Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2025 $554.0 Million -$404.0 Million $83.0 Million
Q1 2025 $466.0 Million -$520.0 Million $27.0 Million
Q4 2024 $2.4 Billion -$426.0 Million -$339.0 Million
Q3 2024 $2.1 Billion -$346.0 Million $312.0 Million
Q2 2024 $200.0 Million -$461.0 Million -$28.0 Million
Q1 2024 $521.0 Million -$354.0 Million -$204.0 Million
Q4 2023 $2.1 Billion -$378.0 Million -$3.0 Billion
Q3 2023 $1.2 Billion -$332.0 Million -$307.0 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions